Shanghai Henlius Biotech Announces IND Approval for HLX316 – A First-in-Class B7-H3-Targeting Sialidase Fc Fusion Protein

Key Highlights

• National Medical Products Administration (NMPA) Approval: Shanghai Henlius Biotech, Inc. has received approval from the NMPA for its investigational new drug (IND) application to initiate a phase 1 clinical trial of HLX316 for injection. HLX316 is a B7-H3-targeting sialidase Fc fusion protein, developed for the treatment of patients with advanced or metastatic solid tumors.
• Novel Mechanism of Action: HLX316 is a first-in-class therapeutic candidate. It combines a proprietary heavy-chain-only antibody variable domain (VHH) targeting B7-H3 with a sialidase bifunctional fusion protein licensed from Palleon Pharmaceuticals Inc. in May 2024. The molecule is engineered to block immune checkpoints by enzymatically cleaving immunosuppressive sialylated glycans, thereby enhancing anti-tumor immune responses without causing systemic immune activation.
• Pre-clinical Efficacy: Pre-clinical studies indicate HLX316 has potent, antigen-directed desialylation effects on tumor cells in vitro, inhibits tumor growth in humanized mouse models, and may offer significant therapeutic benefit for advanced solid tumors.
• Market Opportunity: As of the announcement date, no B7-H3-targeting sialidase Fc fusion protein has been approved for marketing anywhere in the world. Henlius is positioned at the forefront of this innovative approach, which could represent a major breakthrough in cancer immunotherapy.

Implications for Shareholders and Potential Investors

• Potential Price Sensitivity: The approval of the IND application by the NMPA is a significant milestone. It enables the company to advance HLX316 into clinical development, potentially opening new revenue streams if successful. As a first-in-class asset with promising pre-clinical data, HLX316 could enhance Henlius’s competitiveness and market value in the oncology sector.
• Risk Factors: Despite this positive development, Henlius cautions that there is no guarantee of successful clinical development or eventual commercialization. The clinical trial process is inherently risky and subject to regulatory, scientific, and competitive uncertainties.
• Board Composition: The board of directors comprises a mix of executive and non-executive members, including Chairman Wenjie Zhang, and several independent directors, ensuring oversight and governance for shareholders.

In-Depth Details

• HLX316 is a heterodimer composed of two main components:
  • An engineered human sialidase Neu2, which offers improved stability and manufacturability compared to wild-type Neu2, fused to a human IgG1 Fc region.
  • A heavy chain-only antibody variable region (VHH) that specifically binds to human B7-H3, also fused to a human IgG1 Fc region.

  This structure enables HLX316 to precisely target B7-H3-expressing tumors and modulate the immune environment at the tumor site.

• HLX316 was co-developed with technology licensed from Palleon Pharmaceuticals Inc. in May 2024, further enhancing its innovative profile.
• The investigational drug’s mechanism is designed to reduce tumor immune evasion by cleaving sialylated glycans, a known driver of immune suppression in the tumor microenvironment.
• The IND approval signals that HLX316 has met regulatory requirements to begin human testing, marking an important step in its potential path to market.

Investor Warning

Shanghai Henlius Biotech, Inc. has explicitly stated that the successful development and commercialization of HLX316 cannot be guaranteed. Investors are advised to exercise caution and recognize that clinical trial outcomes, regulatory hurdles, and competitive dynamics may affect the company’s share price.

Potential Share Price Impact

The IND approval for HLX316 is a material event that may positively influence investor sentiment and share price, given its first-in-class status and the lack of similar drugs approved globally. However, risks remain, and prudent assessment is advised.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The information herein is based on official company announcements and is subject to change. Shanghai Henlius Biotech, Inc. cannot guarantee the successful development or commercialization of HLX316. Shareholders and prospective investors should exercise caution.

View HENLIUS Historical chart here